Clinical Diagnosis

The otopalatodigital (OPD) spectrum disorders, a heterogeneous group of disorders characterized primarily by a skeletal dysplasia of variable severity, include the following [Verloes et al 2000]:

• Otopalatodigital syndrome type I (OPD1)

• Otopalatodigital syndrome type II (OPD2)

• Frontometaphyseal dysplasia (FMD)

• Melnick-Needles syndrome (MNS)

The diagnosis of the OPD syndromes is made by a combination of clinical examination, radiologic studies, family history consistent with X-linked inheritance, and molecular genetic testing. Clinical findings are summarized in Tables 1 and 2. Radiologic findings are presented in Table 3.

Molecular Genetic Testing

Gene. FLNA is the only gene in which mutation is currently known to be associated with the otopalatodigital (OPD) spectrum disorders.

Clinical testing

• Sequence analysis of entire coding region and of select exons:

  • OPD1. Sequencing of FLNA exons 3-5

  • OPD2. Sequencing of FLNA exons 3-5. If the proband is female, additional exons to consider include exons 11 and 28-29.

  • FMD. FLNA mutations are widespread throughout the gene in individuals with this diagnosis. Initial screening (by either direct sequencing or DHPLC) of select exons may include exons 3-5, 22, 28-29, and 44-47.

  • MNS. Twelve females with this diagnosis have one of the three mutations found within exon 22: p.Asp1184Glu (n=1), p.Ala1188Thr (n=5), and p.Ser1199Leu (n=6) (Genotype-Phenotype Correlations). A logical strategy for molecular analysis of an individual with this condition is to sequence exon 22.

• Deletion/duplication analysis. No deletions or duplications of FLNA have been reported to be causative of otopalatodigital syndrome. However, with newly available deletion/duplication testing methods, it may be appropriate in some instances to test symptomatic individuals who had a negative test result by sequence analysis of the entire coding region.

Research testing. Mutation scanning of the entire gene

Table 4. Summary of Molecular Genetic Testing Used in Otopalatodigital Spectrum Disorders

View in own window

Gene Symbol	Test Method	Phenotype	Mutations Detected	Mutation Detection Frequency 1, 2	Test Availability
FLNA	Sequence analysis of entire gene or select exons	OPD1	Missense mutations in exons 3-5	43% (n=7)	Clinical
		OPD2	Missense mutations	69% (n=13)
		FMD	Sequence variants	57% (n=23) 3
		MNS	Missense mutations in exon 22	100% (n=12)
	Deletion / duplication analysis 4	Undefined 5	Partial- and whole-gene deletions / duplications	Unknown

Test Availability refers to availability in the GeneTests Laboratory Directory. GeneReviews designates a molecular genetic test as clinically available only if the test is listed in the GeneTests Laboratory Directory by either a US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does not verify laboratory-submitted information or warrant any aspect of a laboratory's licensure or performance. Clinicians must communicate directly with the laboratories to verify information.

1. The ability of the test method used to detect a mutation that is present in the indicated gene

2. Analysis by mutation scanning of entire gene [Robertson et al 2006b]

3. Robertson et al [2006a]

4. Testing that identifies deletions/duplications not detectable by sequence analysis of genomic DNA; a variety of methods including quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and array GH may be used.

5. Large deletions and duplications have been associated with allelic conditions such as myxomatous cardiac valvular dystrophy (see Genetically Related Disorders).

Interpretation of test results. For issues to consider in interpretation of sequence analysis results, click here.

Testing Strategy

Confirming the diagnosis in a proband. Clinical diagnosis may guide the order of screening of select exons of FLNA.

Carrier testing for at-risk relatives requires prior identification of the disease-causing mutation in the family.

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the disease-causing mutation in the family.

Note: It is the policy of GeneReviews to include clinical uses of testing available from laboratories listed in the GeneTests Laboratory Directory; inclusion does not necessarily reflect the endorsement of such uses by the author(s), editor(s), or reviewer(s).

Genetically Related (Allelic) Disorders

Periventricular nodular heterotopia, X-linked. This neuronal migration disorder is characterized by the presence of uncalcified nodules of neurons ectopically situated along the surface of the lateral ventricles. Affected individuals are predominantly heterozygous females; males show early lethality. Affected females present with seizures on average at age 14 to 15 years; intelligence ranges from normal to borderline functioning. The risk for stroke and other vascular problems/coagulopathies appears to be increased [Sheen et al 2005].

Loss-of-function mutations spread broadly throughout FLNA are causative [Fox et al 1998, Sheen et al 2001]; however, there is some bias toward clustering within exons encoding the actin-binding domain of filamin A [Parrini et al 2006]. Germline mutations leading to null alleles are found almost exclusively in females, whereas missense mutations or mosaicism for truncating mutations can account for affected males or a mild phenotype in females [Guerrini et al 2004].

A variant of X-linked periventricular nodular heterotopia with marked connective tissue dysfunction (skin fragility, vascular dilatation) described in females [Sheen et al 2005] has been associated with eight mutations in FLNA predicted to lead to loss of function [Sheen et al 2005, Gómez-Garre et al 2006].

Gastrointestinal dysmotility has long been associated with periventricular nodular heterotopia:

• A family with the severe gastrointestinal dysmotility phenotype, chronic intestinal pseudo-obstruction, had a p.Thr23AlafsX82 mutation in FLNA that may favor preferential initiation of translation at a methionine codon 3’ to the conventional start site [Gargiulo et al 2007]. It is unclear whether periventricular nodular heterotopia cosegregated with intestinal pseudo-obstruction in this family.

• Hehr et al [2006] reported a similar presentation associated with the splice site mutation p.Tyr643GlyfsX39.

One female has been reported with a dual phenotype of periventricular nodular heterotopia and FMD caused by a mutation variably leading to either a substitution or a small deletion as a result of aberrant splicing [Zenker et al 2004].

Myxomatous cardiac valvular dystrophy. Kyndt et al [2007] described this disorder, which is not associated with other neurologic or skeletal manifestations in four unrelated families in which three missense mutations and a g.10807_12749delinsTG mutation were identified. All mutations lead to substitutions or deletion of amino acids in the most N terminal third of the protein. Of note, cardiac valvular anomalies are associated with X-linked periventricular nodular heterotopia.

Natural History

Little is known about the natural history of the otopalatodigital (OPD) spectrum disorders. All manifestations can begin in childhood in both sexes.

In males, the spectrum of severity ranges from mild manifestations in otopalatodigital syndrome type I (OPD1), to a more severe presentation in frontometaphyseal dysplasia (FMD) and otopalatodigital syndrome type II (OPD2). Prenatal lethality is the most common clinical phenotype in males with Melnick-Needles syndrome (MNS) [Donnenfeld et al 1987].

Females exhibit variable expressivity. In OPD1, females can present with similar severity to affected males. In contrast, some females have only the mildest of manifestations [Gorlin et al 1973]. In OPD2 and FMD, females are less severely affected than related affected males [Fitzsimmons et al 1982, Robertson et al 1997].

Otopalatodigital syndrome type I. Most manifestations are evident at birth. Nothing reported in the literature suggests any late-onset orthopedic complications, reduction in longevity, or reduction in fertility.

Final height can be mildly reduced, but individuals have been characterized with mutations in FLNA and stature greater than the 90th percentile. Pubertal development and intelligence is normal in affected individuals.

Carrier females may develop conductive or neurosensory hearing loss.

Otopalatodigital syndrome type II. Most affected males do not survive beyond the first year of life, usually secondary to thoracic hypoplasia with resulting pulmonary insufficiency.

Males who live beyond the first year of life are usually developmentally delayed and require assistance with feeding and respiratory support.

Frontometaphyseal dysplasia. Males do not experience progression of their skeletal dysplasia but may develop secondary complications of joint contractures. Progressive scoliosis has been described in both males and females.

Melnick-Needles syndrome. Substantial variability is observed. Some individuals are diagnosed in adulthood after ascertainment of an affected family member [Kristiansen et al 2002]. Others require substantial respiratory support; several individuals have required ambulatory oxygen supplementation, typically starting in the second decade. Longevity is reduced in these individuals. Occasionally, males can survive the neonatal period but do not live beyond the first year of life [Robertson et al 1997, Verloes et al 2000].

Genotype-Phenotype Correlations

Mutations associated with the OPD spectrum disorders are predicted to maintain the translational reading frame and to produce full-length protein. These mutations are clustered in discrete regions of the gene. Genotype-phenotype correlation is strong. Two large studies have been published to date [Robertson et al 2006a]:

• Otopalatodigital syndrome type I. All males with this diagnosis had mutations in exons 3, 4, or 5 (see Table 7; pdf).

• Otopalatodigital syndrome type II. All males with this diagnosis had mutations in exons 3, 4, or 5. Females with a phenotype similar to males with typical OPD2 had mutations in exons 28 and 29 (see Table 7).

• Frontometaphyseal dysplasia

  • Nine out of 12 males with FMD had mutations in FLNA (exons 3-5, 22, 28-29) [Robertson et al 2006a]. Mutations in females with FMD (found in 57% of affected females) are more widely distributed over the gene (exons 3-5, 11, 22, 28-29, 44-47) than mutations identified in males.

  • One female with a combined FMD-periventricular nodular heterotopia phenotype had a missense mutation that also created an ectopic splice site [Zenker et al 2004] (see Table 7).

  • Some mutations are associated with a male-lethal phenotype caused by cardiac and urologic malformations [Stefanova et al 2005, Robertson et al 2006a].

  • No clinical distinction is observed between individuals with FMD and an FLNA mutation and those without such a mutation [Robertson et al 2006a].

• Melnick-Needles syndrome. Twelve affected females had one of three mutations in exon 22 of FLN, resulting in the following amino acid changes: p.Asp1184Glu (n=1), p.Ala1188Thr (n=5), and p.Ser1199Leu (n=6) (see Table 7).

Penetrance

Penetrance in males with an FLNA mutation leading to an OPD spectrum disorder is complete.

Some obligate carrier females with FLNA mutations leading to OPD1 have a normal clinical appearance. It is unclear what proportion of such females have radiographic indicators of their carrier status.

Anticipation

No evidence suggests genetic anticipation in these disorders.

Nomenclature

The term “otopalatodigital syndrome spectrum disorders” is an umbrella category for four discrete but clinically related conditions, namely: frontometaphyseal dysplasia, Melnick-Needles syndrome (originally referred to as osteodysplasty), otopalatodigital syndrome type I (also called Taybi syndrome after its first description in 1963), and otopalatodigital syndrome type II. The term “spectrum” reflects the fact that, although most individuals can be unambiguously diagnosed with one of the constituent phenotypes, overlapping of the phenotypes has been observed.

Verloes et al [2000] suggested the term "fronto-otopalatodigital osteodysplasia" for the otopalatodigital spectrum disorders, indicative of his prediction that they would prove allelic to one another. This term has not gained acceptance because these disorders are clinically discrete, and therefore diagnosis, management, and prognostication are not served by lumping them under one term.

Prevalence

No population-based studies have been performed to assess prevalence adequately.

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with otopalatodigital (OPD) spectrum disorders, the following evaluations are recommended:

• Full clinical examination

• Full radiologic skeletal survey

• Audiometry (see Deafness and Hereditary Hearing Loss Overview)

• Ear, nose, and throat examination

• Renal tract ultrasound examination

Treatment of Manifestations

• Deafness is managed with hearing aids (see Deafness and Hereditary Hearing Loss Overview). The conductive hearing loss can be caused by fused and misshapen ossicles; attempts to separate the ossicles are usually unsuccessful and can lead to formation of a perilymphatic gusher.

• Stridor in the neonatal period on account of laryngeal stenosis rarely requires surgical intervention and is non-progressive with growth.

• Cosmetic surgery to correct the fronto-orbital deformity has been attempted in some individuals. Re-growth post surgery does not seem to occur [Kung & Sloan 1998]. Hand and foot malformations may also require surgery.

• Orthopedic surgery

  • Surgical correction of limb bowing has not been reported.

  • Several individuals have had scoliosis surgically addressed, with satisfactory results.

  • Chest expansion surgery has been attempted in several individuals with Melnick-Needles syndrome, with only marginal clinical benefit.

• Apnea prevention. Micrognathia and tracheobronchomalacia in severely affected individuals can lead to airway collapse and sleep apnea that have been successfully corrected with continuous positive airway pressure (CPAP) [Lan et al 2006].

Prevention of Secondary Complications

Anesthetists should be aware of the associated laryngeal stenosis, if intubation and ventilation are required [Leggett 1988, Mehta & Schou 1988].

Surveillance

Clinical evaluation for development of orthopedic manifestations (e.g., hand contractures in FMD, scoliosis in FMD and MNS) is appropriate.

Monitoring of hearing loss should be ongoing, as the sensorineural component can be progressive.

Testing of Relatives at Risk

Consider molecular genetic testing for the family-specific mutation in all at-risk relatives

Because affected individuals may benefit from early evaluations for hearing loss and orthopedic complications, including scoliosis, molecular genetic testing for the family-specific mutation in all at-risk relatives should be considered.

If molecular genetic testing is not an option for an at-risk child, evaluations for hearing loss and orthopedic complications, including scoliosis, should be instituted as soon as possible after a clinical diagnosis is established in the at-risk relative.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Other

Genetics clinics, staffed by genetics professionals, provide information for individuals and families regarding the natural history, treatment, mode of inheritance, and genetic risks to other family members as well as information about available consumer-oriented resources. See the GeneTests Clinic Directory.

See Consumer Resources for disease-specific and/or umbrella support organizations for this disorder. These organizations have been established for individuals and families to provide information, support, and contact with other affected individuals.

Mode of Inheritance

The otopalatodigital spectrum disorders (OPD spectrum disorders) are inherited in an X-linked manner.

Risk to Family Members — OPD1, OPD2, or Frontometaphyseal Dysplasia (FMD)

Parents of a male proband with OPD1, OPD2, or FMD

• The father of an affected male will not have the disease nor will he be a carrier of the mutation.

• In a family with more that one affected individual, the mother of an affected male is an obligate carrier.

• If pedigree analysis reveals that the proband is the only affected family member, four possible genetic explanations exist:

  • The proband has a de novo mutation. In this instance, the proband's mother does not have a gene mutation; and the only other family members at risk are the offspring of the proband. De novo mutations are common in the otopalatodigital spectrum disorders.

  • The proband's mother has a de novo mutation. Two types of de novo mutations may be present in the mother:
    
    a. A de novo germline mutation that was present at the time of her conception, is present in every cell of her body, and is detectable in DNA extracted from her leukocytes
    OR
    
    b. A mutation that is present in some of her germ cells only (termed "germline mosaicism") and is not detectable in DNA extracted from her leukocytes. Germline mosaicism has been reported in otopalatodigital syndrome type I and therefore should be considered in the genetic counseling of at-risk family members [Robertson et al 2006b].
    
    In both instances (a. and b.) each of the proband’s mother’s offspring is at risk of inheriting the mutation; none of the proband’s mother’s sibs, however, is at risk of inheriting the mutation.

  • The mother is a carrier and has inherited the disease-causing mutation either from her mother, who has a disease-causing mutation, or from her asymptomatic father, who is mosaic for the mutation.

Parents of a female proband with OPD1, OPD2, or FMD

• If the proband is a female with OPD1, OPD2, or FMD, and if pedigree analysis reveals that she is the only affected family member, it is reasonable to offer molecular genetic testing to both of her parents to determine risks to family members.

• If the proband’s father is asymptomatic, it is possible that he has the mutation in some cells in his body (somatic mosaicism). If her father is asymptomatic and does not have somatic mosaicism for the altered gene, the possible genetic explanations for the origin of the proband’s gene mutation are the same as for a male proband with a negative family history.

• Somatic mosaicism for mutations leading to the OPD spectrum disorders has been described and has the potential to modify the expressivity of these disorders [Robertson et al 2006b].

Sibs of a male proband with OPD1, OPD2, or FMD

• The risk to the sibs of a proband depends on the genetic status of the parents.

• If a parent has an FLNA mutation, the chance of transmitting the mutation in each pregnancy is 50%:

  • When the mother has an FLNA mutation, male sibs who inherit the mutation will be affected; female sibs who inherit the mutation will have a range of possible phenotypic expression.

  • When the father has an FLNA mutation, all female sibs will inherit the mutation; male sibs will not inherit the mutation.

• When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low but greater than that of the general population:

  • If the disease-causing mutation cannot be detected in the DNA of either parent of the proband, two possible explanations are germline mosaicism in a parent or a de novo mutation in the proband.

  • Germline mosaicism has been observed in a family with otopalatodigital syndrome type I and is therefore a possibility.

Offspring of a male proband with OPD1, OPD2, or FMD. Males with OPD2 do not reproduce. Males with OPD1 or FMD transmit the disease-causing mutation to all of their daughters and none of their sons.

Offspring of a female proband with OPD1, OPD2, or FMD. Women with an FLNA mutation have a 50% chance of transmitting the disease-causing mutation to each child: sons who inherit the mutation will be affected; daughters will have a range of possible phenotypic expression.

Other family members of a proband with OPD1, OPD2, or FMD. If a parent of the proband is found to also have a disease-causing mutation, his or her female family members may be at risk of having the mutation and being asymptomatic or symptomatic; and his or her male family members may be at risk of being affected depending on their genetic relationship to the proband.

Risk to Family Members — Melnick-Needles Syndrome (MNS)

Parents of a male proband with MNS

• The father of an affected male will not have the disease nor will he be a carrier of the mutation.

• In a family with affected individuals in more than one generation, the mother of an affected male is an obligate carrier.

• If pedigree analysis reveals that the proband is the only affected family member, four possible genetic explanations exist:

  • The proband has a de novo mutation, in which case the proband's mother does not have a gene mutation. De novo mutations are common in the otopalatodigital spectrum disorders.

  • The proband's mother has a de novo mutation. Two types of de novo mutations may be present in the mother:

    a.

    A germline mutation that was present at the time of her conception. It is present in every cell of her body and is detectable in DNA extracted from her leukocytes
    OR

    b.

    A mutation that is present in some of her germ cells only (termed "germline mosaicism") and is not detectable in DNA extracted from her leukocytes. Germline mosaicism has been demonstrated in the otopalatodigital spectrum disorders.
    
    In both instances (a. and b.) each of the proband's mother's offspring is at risk of inheriting the mutation; none of the proband's mother's sibs, however, is at risk of inheriting the mutation.

  • The mother is a carrier and has inherited the disease-causing mutation from her mother who has a disease-causing mutation.

Parents of a female proband with MNS. If the proband is a female and if pedigree analysis reveals that she is the only affected family member, it is reasonable to offer molecular genetic testing to her mother to determine risks to family members.

Sibs of a proband with MNS

• The risk to the sibs of a proband depends on the genetic status of the mother.

• If the mother has the gene mutation, the chance of transmitting the FLNA mutation in each pregnancy is 50%:

  • Male sibs who inherit the mutation will be affected and generally die prenatally or perinatally; female sibs who inherit the mutation will have a range of possible phenotypic expression.

• When the mother is clinically unaffected, the risk to the sibs of a proband appears to be low but greater than that of the general population:

  • If the disease-causing mutation cannot be detected in the DNA of the mother of the proband, two possible explanations are germline mosaicism in a parent or a de novo mutation in the proband.

  • Germline mosaicism has been observed in a female with a mutation leading to otopalatodigital syndrome type I.

Offspring of a male proband with MNS. Males with MNS usually die in the pre- or perinatal period and do not reproduce.

Offspring of a female proband with MNS. Women with an FLNA mutation have a 50% chance of transmitting the disease-causing mutation to each child; sons who inherit the mutation will be affected and generally die prenatally; daughters will have a range of possible phenotypic expression.

Carrier Detection

Carrier testing for at-risk family members is available on a clinical basis once the FLNA mutation has been identified in the family.

Related Genetic Counseling Issues

See Management, Testing of Relatives at Risk for information on testing at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk and discussion of prenatal testing is before pregnancy.

• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. See for a list of laboratories offering DNA banking.

Prenatal Testing

Molecular genetic testing. Prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation or chorionic villus sampling (CVS) at approximately ten to 12 weeks' gestation. The disease-causing allele of an affected family member must be identified before prenatal testing can be performed.

Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.

Ultrasound examination. Many of the manifestations of the disorder can be visualized prenatally by ultrasound examination, although the gestational age at which various anomalies can be detected differs. An omphalocele or urinary tract severely dilated by obstruction may be visible from very early in the second trimester. In contrast, the skeletal dysplasia with its associated limb bowing and thoracic hypoplasia may be visible only after 20 weeks' gestation [Eccles et al 1994].

Preimplantation genetic diagnosis (PGD) may be available for families in which the disease-causing mutation has been identified. For laboratories offering PGD, see .

Molecular Genetic Pathogenesis

The filamin class of actin-binding proteins is known to regulate cell stability, protrusion, and motility across various biologic systems [Gorlin et al 1990, Cunningham et al 1992, Ott et al 1998, Leonardi et al 2000, Stahlhut & van Deurs 2000]. Filamin-deficient melanocytes fail to undergo locomotion in response to factors that elicit migration in the same filamin-expressing cells. They exhibit prolonged circumferential blebbing, abnormal phagocytosis, and impaired volume regulation, perhaps secondary to abnormal regulation of sodium channel activity. A similar defect is observed in filamin-deficient macrophages with disruption of myosin during spreading and phagocytosis [Stendahl et al 1980]. Filamin is also required for cell motility and pseudopod formation in the slime mold, Dictyostelium discoideum, suggesting a highly conserved function across species [Cox et al 1996]. A direct mechanism can be drawn with the association of filamin and integrins, which have been implicated in cell adhesion and migration.

The contrast in phenotypic consequences among loss-of-function mutations (leading to periventricular nodular heterotopia) and clustered missense mutations (leading to the OPD spectrum disorders) suggests that different mechanisms are contributing to the pathogenesis of these conditions. Filamins coordinate and integrate cell signaling and subsequent remodeling of the actin cytoskeleton. The complexity of these integrative functions makes the implication of individual functions in the pathogenesis of these conditions difficult. However, filamin associates with integrins, which regulate such cellular processes as cell adhesion and neuronal migration [Meyer et al 1997, Loo et al 1998, Dulabon et al 2000]. Filamin A may have a similar influence on neuroblast migration during cortical development within the central nervous system. Disruption of this process likely results in the formation of periventricular heterotopias. Similarly, filamins regulate signal transduction by transmembrane receptors and second messengers, the disruption of which could lead to developmental defects such as those observed in the OPD spectrum disorder phenotypes.

Normal allelic variants. As with other loci within Xq28, the level of polymorphism in FLNA is low. Several synonymous and nonsynonymous variants have been shown to be present in healthy individuals (see Table 5; pdf), including some that have been reported in the literature (incorrectly) as causal of disease phenotypes [Masruha et al 2006]. FLNA, which encodes the protein filamin A, encompasses 48 exons spread over 26 kb on chromosome Xq28. The FLNA transcript is 8.3 kb (see Table 5; pdf).

Pathologic allelic variants. Mutations that lead to the otopalatodigital spectrum disorders are substitutions or small deletions of amino acid residues. These alterations occur in defined regions of the filamin A protein (see Abnormal gene product). Substitutions in the distal portion of the actin-binding domain (termed calponin homology domain 2) lead to OPD1 and OPD2. In contrast, only three mutations (two of them highly recurrent and located within exon 22) lead to Melnick-Needles syndrome. Mutations that lead to frontometaphyseal dysplasia are the most widely dispersed, being located in regions that encode the actin binding domain, repeats 3, 9/10, 14/15, and 22/23. This distribution of mutations indicates that very specific functions of filamins are being altered to lead to the OPD spectrum disorders, in contrast to a global loss of function that results in the periventricular nodular heterotopia phenotype.

See Table 7 (pdf).

Normal gene product. Filamin A is a 280-kd filamentous protein comprising 2647 amino acids. The protein links membrane receptors to the actin cytoskeleton and represents a crucial link between signal transduction and the cytoskeleton. The protein consists of an actin-binding domain at the amino terminus, 23 repeats that resemble Ig-like domains and which form a chain-like structure interrupted by two hinge regions, and a C-terminal repeat that undergoes dimerization. There are two principal isoforms of the protein, produced from alternative splicing of exon 32 that encodes a “hinge” domain. Two other filamins, filamin B and filamin C, are encoded by autosomal loci and share significant similarity at the protein level.

Abnormal gene product. Mutations that lead to the otopalatodigital spectrum disorders are predicted to result in filamin A proteins with substitutions or small deletions of amino acid residues. These alterations occur in defined regions of the filamin A protein (see Pathologic allelic variants). This distribution of mutations indicates that very specific functions of filamins are being altered to lead to the OPD spectrum disorders, in contrast to a global loss of function that results in the periventricular nodular heterotopia phenotype. This pattern of clustered missense mutations suggests that key interactions with filamin or localized domains of filamin that have regulatory functions are altered by these mutations. No specific functions of filamin have been unequivocally linked to the pathogenesis of the OPD spectrum disorders to date.

Literature Cited

1. Albano LM, Bertola DR, Barba MF, Valente M, Robertson SP, Kim CA. Phenotypic overlap in Melnick-Needles, serpentine fibula-polycystic kidney and Hajdu-Cheney syndromes: a clinical and molecular study in three patients. Clin Dysmorphol. 2007;16:27–33. [PubMed: 17159511]
2. André M, Vigneron J, Didier F. Abnormal facies, cleft palate, and generalized dysostosis: a lethal X-linked syndrome. J Pediatr. 1981;98:747–52. [PubMed: 7229752]
3. Brewster TG, Lachman RS, Kushner DC, Holmes LB, Isler RJ, Rimoin DL. Oto-palato-digital syndrome, type II — an X-linked skeletal dysplasia. Am J Med Genet. 1985;20:249–54. [PubMed: 3976718]
4. Cox D, Wessels D, Soll DR, Hartwig J, Condeelis J. Re-expression of ABP-120 rescues cytoskeletal, motility, and phagocytosis defects of ABP-120- Dictyostelium mutants. Mol Biol Cell. 1996;7:803–23. [PMC free article: PMC275931] [PubMed: 8744952]
5. Cunningham CC, Gorlin JB, Kwiatkowski DJ, Hartwig JH, Janmey PA, Byers HR, Stossel TP. Actin-binding protein requirement for cortical stability and efficient locomotion. Science. 1992;255:325–7. [PubMed: 1549777]
6. Dereymaeker AM, Christens J, Eeckels R, Heremans G, Fryns JP. Melnick-Needles syndrome (osteodysplasty). Clinical and radiological heterogeneity. Helv Paediatr Acta. 1986;41:339–51. [PubMed: 3793511]
7. Donnenfeld AE, Conard KA, Roberts NS, Borns PF, Zackai EH. Melnick-Needles syndrome in males: a lethal multiple congenital anomalies syndrome. Am J Med Genet. 1987;27:159–73. [PubMed: 3605194]
8. Dudding BA, Gorlin RJ, Langer LO. The oto-palato-digital syndrome. A new symptom-complex consisting of deafness, dwarfism, cleft palate, characteristic facies, and a generalized bone dysplasia. Am J Dis Child. 1967;113:214–21. [PubMed: 6019437]
9. Dulabon L, Olson EC, Taglienti MG, Eisenhuth S, McGrath B, Walsh CA, Kreidberg JA, Anton ES. Reelin binds alpha3beta1 integrin and inhibits neuronal migration. Neuron. 2000;27:33–44. [PubMed: 10939329]
10. Eccles DM, Moore IE, Cook S, Griffin DR, Chitty L, Hall CM, Temple IK. Prenatal ultrasound findings in a fetus with otopalatodigital syndrome type II. Clin Dysmorphol. 1994;3:175–9. [PubMed: 8055140]
11. Fitch N, Jequier S, Gorlin R. The oto-palato-digital syndrome, proposed type II. Am J Med Genet. 1983;15:655–64. [PubMed: 6614053]
12. Fitch N, Jequier S, Papageorgiou A. A familial syndrome of cranial, facial, oral and limb anomalies. Clin Genet. 1976;10:226–31. [PubMed: 975599]
13. Fitzsimmons JS, Fitzsimmons EM, Barrow M, Gilbert GB. Fronto-metaphyseal dysplasia. Further delineation of the clinical syndrome. Clin Genet. 1982;22:195–205. [PubMed: 7151303]
14. Fox JW, Lamperti ED, Eksioglu YZ, Hong SE, Feng Y, Graham DA, Scheffer IE, Dobyns WB, Hirsch BA, Radtke RA, Berkovic SF, Huttenlocher PR, Walsh CA. Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron. 1998;21:1315–25. [PubMed: 9883725]
15. Gargiulo A, Auricchio R, Barone MV, Cotugno G, Reardon W, Milla PJ, Ballabio A, Ciccodicola A, Auricchio A. Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement. Am J Hum Genet. 2007;80:751–8. [PMC free article: PMC1852717] [PubMed: 17357080]
16. Gómez-Garre P, Seijo M, Gutiérrez-Delicado E, Castro del Río M, de la Torre C, Gómez-Abad C, Morales-Corraliza J, Puig M, Serratosa JM. Ehlers-Danlos syndrome and periventricular nodular heterotopia in a Spanish family with a single FLNA mutation. J Med Genet. 2006;43:232–7. [PMC free article: PMC2563248] [PubMed: 15994863]
17. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ, Hartwig JH. Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a molecular leaf spring. J Cell Biol. 1990;111:1089–105. [PMC free article: PMC2116286] [PubMed: 2391361]
18. Gorlin RJ, Cohen MM. Frontometaphyseal dysplasia. A new syndrome. Am J Dis Child. 1969;118:487–94. [PubMed: 5807657]
19. Gorlin RJ, Winter RB. Frontometaphyseal dysplasia — evidence for X-linked inheritance. Am J Med Genet. 1980;5:81–4. [PubMed: 7395904]
20. Gorlin RJ, Poznanski AK, Hendon I. The oto-palato-digital (OPD) syndrome in females. Oral Surg Oral Med Oral Pathol. 1973;35:218–24. [PubMed: 4513067]
21. Guerrini R, Mei D, Sisodiya S, Sicca F, Harding B, Takahashi Y, Dorn T, Yoshida A, Campistol J, Krämer G, Moro F, Dobyns WB, Parrini E. Germline and mosaic mutations of FLN1 in men with periventricular heterotopia. Neurology. 2004;63:51–6. [PubMed: 15249610]
22. Hehr T, Classen J, Welz S, Ganswindt U, Scheithauer H, Koitschev A, Bamberg M, Budach W. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. Radiother Oncol. 2006;80:33–8. [PubMed: 16875750]
23. Kanemura T, Orii T, Ohtani M. Frontometaphyseal dysplasia with congenital urinary tract malformations. Clin Genet. 1979;16:399–404. [PubMed: 527247]
24. Kristiansen M, Knudsen GP, Soyland A, Westvik J, Orstavik KH. Phenotypic variation in Melnick-Needles syndrome is not reflected in X inactivation patterns from blood or buccal smear. Am J Med Genet. 2002;108:120–7. [PubMed: 11857561]
25. Kung DS, Sloan GM. Cranioplasty in frontometaphyseal dysplasia. Plast Reconstr Surg. 1998;102:1144–6. [PubMed: 9734434]
26. Kyndt F, Le Scouarnec S, Jaafar P, Gueffet JP, Legendre A, Trochu JN, Jousseaume V, Chaventré A, Schott JJ, Le Marec H, Probst V. Genetic aspects of valvulopathies. Arch Mal Coeur Vaiss. 2007;100:1013–20. [PubMed: 18223515]
27. Lan CC, Hung KF, Liao YF, Lin SW, Chen NH. Melnick-Needles syndrome with obstructive sleep apnea successfully treated with nasal continuous positive airway pressure ventilation. J Formos Med Assoc. 2006;105:77–9. [PubMed: 16440074]
28. Leggett JM. Laryngo-tracheal stenosis in frontometaphyseal dysplasia. J Laryngol Otol. 1988;102:74–8. [PubMed: 3343570]
29. Leonardi A, Ellinger-Ziegelbauer H, Franzoso G, Brown K, Siebenlist U. Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2. J Biol Chem. 2000;275:271–8. [PubMed: 10617615]
30. Loo DT, Kanner SB, Aruffo A. Filamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interaction. J Biol Chem. 1998;273:23304–12. [PubMed: 9722563]
31. Masruha MR, Caboclo LO, Carrete H, Cendes IL, Rodrigues MG, Garzon E, Yacubian EM, Sakamoto AC, Sheen V, Harney M, Neal J, Sean Hill R, Bodell A, Walsh C, Vilanova LC. Mutation in filamin A causes periventricular heterotopia, developmental regression, and West syndrome in males. Epilepsia. 2006;47:211–4. [PubMed: 16417552]
32. Mehta Y, Schou H. The anaesthetic management of an infant with frontometaphyseal dysplasia (Gorlin-Cohen syndrome). Acta Anaesthesiol Scand. 1988;32:505–7. [PubMed: 3176838]
33. Melnick JC, Needles CF. An undiagnosed bone dysplasia. A 2 family study of 4 generations and 3 generations. Am J Roentgenol Radium Ther Nucl Med. 1966;97:39–48. [PubMed: 5938049]
34. Meyer U, Meyer T, Jones DB. No mechanical role for vinculin in strain transduction in primary bovine osteoblasts. Biochem Cell Biol. 1997;75:81–7. [PubMed: 9192077]
35. Morava E, Illés T, Weisenbach J, Kárteszi J, Kosztolányi G. Clinical and genetic heterogeneity in frontometaphyseal dysplasia: severe progressive scoliosis in two families. Am J Med Genet A. 2003;116A:272–7. [PubMed: 12503106]
36. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol. 1998;140:1241–53. [PMC free article: PMC2132689] [PubMed: 9490735]
37. Parrini E, Ramazzotti A, Dobyns WB, Mei D, Moro F, Veggiotti P, Marini C, Brilstra EH, Dalla Bernardina B, Goodwin L, Bodell A, Jones MC, Nangeroni M, Palmeri S, Said E, Sander JW, Striano P, Takahashi Y, Van Maldergem L, Leonardi G, Wright M, Walsh CA, Guerrini R. Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain. 2006;129:1892–906. [PubMed: 16684786]
38. Robertson S, Gunn T, Allen B, Chapman C, Becroft D. Are Melnick-Needles syndrome and oto-palato-digital syndrome type II allelic? Observations in a four-generation kindred. Am J Med Genet. 1997;71:341–7. [PubMed: 9268106]
39. Robertson SP, Jenkins ZA, Morgan T, Adès LA, Aftimos S, Boute O, Fiskerstrand T, Garcia-Minãur S, Grix A, Green A, Der Kaloustian V, Lewkonia R, McInnes B, van Haelst MM, Mancini G, Illés T, Mortier G, Newbury-Ecob R, Nicholson L, Scott CI, Ochman K, Brożek I, Shears DJ, Superti-Furga A, Suri M, Whiteford M, Wilkie AO, Krakow D. Frontometaphyseal dysplasia: mutations in FLNA and phenotypic diversity. Am J Med Genet A. 2006a;140:1726–36. [PubMed: 16835913]
40. Robertson SP, Thompson S, Morgan T, Holder-Espinasse M, Martinot-Duquenoy V, Wilkie AO, Manouvrier-Hanu S. Postzygotic mutation and germline mosaicism in the otopalatodigital syndrome spectrum disorders. Eur J Hum Genet. 2006b;14:549–54. [PubMed: 16538226]
41. Sheen VL, Dixon PH, Fox JW, Hong SE, Kinton L, Sisodiya SM, Duncan JS, Dubeau F, Scheffer IE, Schachter SC, Wilner A, Henchy R, Crino P, Kamuro K, DiMario F, Berg M, Kuzniecky R, Cole AJ, Bromfield E, Biber M, Schomer D, Wheless J, Silver K, Mochida GH, Berkovic SF, Andermann F, Andermann E, Dobyns WB, Wood NW, Walsh CA. Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. Hum Mol Genet. 2001;10:1775–83. [PubMed: 11532987]
42. Sheen VL, Jansen A, Chen MH, Parrini E, Morgan T, Ravenscroft R, Ganesh V, Underwood T, Wiley J, Leventer R, Vaid RR, Ruiz DE, Hutchins GM, Menasha J, Willner J, Geng Y, Gripp KW, Nicholson L, Berry-Kravis E, Bodell A, Apse K, Hill RS, Dubeau F, Andermann F, Barkovich J, Andermann E, Shugart YY, Thomas P, Viri M, Veggiotti P, Robertson S, Guerrini R, Walsh CA. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology. 2005;64:254–62. [PubMed: 15668422]
43. Stahlhut M, van Deurs B. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol Biol Cell. 2000;11:325–37. [PMC free article: PMC14777] [PubMed: 10637311]
44. Stefanova M, Meinecke P, Gal A, Bolz H. A novel 9 bp deletion in the filamin a gene causes an otopalatodigital-spectrum disorder with a variable, intermediate phenotype. Am J Med Genet A. 2005;132:386–90. [PubMed: 15654694]
45. Stendahl OI, Hartwig JH, Brotschi EA, Stossel TP. Distribution of actin-binding protein and myosin in macrophages during spreading and phagocytosis. J Cell Biol. 1980;84:215–24. [PMC free article: PMC2110553] [PubMed: 6991506]
46. Stratton RF, Bluestone DL. Oto-palatal-digital syndrome type II with X-linked cerebellar hypoplasia/hydrocephalus. Am J Med Genet. 1991;41:169–72. [PubMed: 1785627]
47. Superti-Furga A, Gimelli F. Fronto-metaphyseal dysplasia and the oto-palato-digital syndrome. Dysmorph Clin Genet. 1987;1:2–5.
48. Taybi H. Generalized skeletal dysplasia with multiple anomalies. A note on Pyle's disease. Am J Roentgenol Radium Ther Nucl Med. 1962;88:450–7. [PubMed: 13919903]
49. Verloes A, Lesenfants S, Barr M, Grange DK, Journel H, Lombet J, Mortier G, Roeder E. Fronto-otopalatodigital osteodysplasia: clinical evidence for a single entity encompassing Melnick-Needles syndrome, otopalatodigital syndrome types 1 and 2, and frontometaphyseal dysplasia. Am J Med Genet. 2000;90:407–22. [PubMed: 10706363]
50. Young K, Barth CK, Moore C, Weaver DD. Otopalatodigital syndrome type II associated with omphalocele: report of three cases. Am J Med Genet. 1993;45:481–7. [PubMed: 8465856]
51. Zaytoun GM, Harboyan G, Kabalan W. The oto-palato-digital syndrome: variable clinical expressions. Otolaryngol Head Neck Surg. 2002;126:129–40. [PubMed: 11870342]
52. Zenker M, Rauch A, Winterpacht A, Tagariello A, Kraus C, Rupprecht T, Sticht H, Reis A. A dual phenotype of periventricular nodular heterotopia and frontometaphyseal dysplasia in one patient caused by a single FLNA mutation leading to two functionally different aberrant transcripts. Am J Hum Genet. 2004;74:731–7. [PMC free article: PMC1181949] [PubMed: 14988809]

Suggested Reading

1. Feng Y, Chen MH, Moskowitz IP, Mendonza AM, Vidali L, Nakamura F, Kwiatkowski DJ, Walsh CA. Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc Natl Acad Sci USA. 2006;103:19836–41. [PMC free article: PMC1702530] [PubMed: 17172441]

Acknowledgments

The author is supported by the Child Health Research Foundation of New Zealand.

Revision History

• 28 April 2009 (cd) Revision: Deletion/duplication analysis available clinically

• 25 July 2008 (me) Comprehensive update posted live

• 30 November 2005 (me) Review posted to live Web site

• 14 March 2005 (sr) Original submission